News | April 21, 2015

Proton Therapy Center Czech uses seed markers for precise tumor targeting across five treatments

Proton Therapy Center Czech, John, Irish, U.K., prostate cancer

April 21, 2015 — The Proton Therapy Center in the Czech Republic treated its first Irish patient for prostate cancer beginning in mid-March.

The PTC is well known to the U.K. audience thanks to the story of the British boy Ashya King. Ashya’s parents chose Prague for his brain tumor treatment to ensure the lowest possible side effects. 

But from the U.K. it is mostly men in their fifties and sixties who come for the proton beam therapy in Prague. That's because proton therapy is highly beneficial for the major male problem of prostate cancer. 

John is 64. His family and background is in Ireland and he often still returns to his home country. He came to the U.K. to work, for more than 25 years, for the military forces.

"I was on active surveillance for 18 months back home but felt like I was awaiting something to happen“, said John, describing his feelings of uncertainty. "At that time, I came across the stories of British patients treated in Prague and sat down to read PTC websites and watch the great videos of the center, located in a city I always wanted to visit. Of course there was also the story of Ashya King in the British media. “ 

John did not hesitate and decided for himself. "I just rang the head nurse of my urologist and announced that I was going for proton therapy. I got a message that the urologist was fine with that." Getting all the medical reports took a bit longer than he had imagined – it was Christmas time. "Once I had my folder I sent it to PTC. There the patient manager called Lucie immediately got in touch. She was very supportive and in constant touch. “

John had never visited Prague although he had always wanted to. He and his wife were impressed. "I liked [the] center from day one”, he said. That was when he came for his first consultation and planning of computed tomography (CT) and magnetic resonance imaging (MRI) scans. Then he went back to the U.K. to get some things sorted and came back in mid-March to start his five sessions of treatment.

It consisted of five fractions only – a major advantage of proton beam therapy which enables higher doses onto the tumor, increasing the efficiency and minimizing the unwanted dose around the tumor. “In early stage cases of prostate cancer, PTC Czech has 97 percent curability and the data corresponds to the world clinical studies on proton therapy,” added Jiri Kubes, M.D., PTC medical director. This is also strengthened by the use of golden seeds – golden markers which help to target the beam even more precisely. These golden pellets are applied directly at PTC.

“So far I feel great,” said John.

For more information: www.proton-cancer-treament.com


Related Content

News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
Feature | Radiation Oncology

The radiation oncology community lost a leader this past summer, with the passing of Jay Loeffler, MD, FACR, FASTRO. He ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | Radiation Oncology

September 13, 2023 — Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients ...

Time September 13, 2023
arrow
News | Radiation Oncology

September 12, 2023 — Michael J. Zelefsky, MD, a renowned leader in radiation oncology, is joining NYU Langone’s ...

Time September 12, 2023
arrow
News | Radiation Oncology

September 6, 2023 — Nina D’Abreo, MD, has been named as chief of the Division of Hematology and Medical Oncology at NYU ...

Time September 06, 2023
arrow
News | Radiation Oncology

August 30, 2023 — Elekta and the IAEA have signed a partnership agreement to jointly pursue common interests, including ...

Time August 30, 2023
arrow
News | Radiation Therapy

August 30, 2023 — A published study by researchers at the University of Cincinnati Cancer Center and Cincinnati Children ...

Time August 30, 2023
arrow
News | Radiopharmaceuticals and Tracers

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that ...

Time August 28, 2023
arrow
Subscribe Now